Qvents

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

Glenmark recall Indomethacin and Naproxe

Glenmark has initiated a Class II recall of 37200 bottles of Indomethacin 25mg capsules and

FDA approves Astra Zeneca’s TRUQAP (ca

AstraZeneca’s TRUQAP (New Molecule Capivasertib) in combination with Faslodex (Fulvestrant) has been approved in the

Cipla Warning letter cites gaps in Compl

The Warning letter (dated November 17, 2023) follows the FDA inspection at Cipla’s Pithampur, Indore

Ascendis Pharma announces European appro

Danish Pharma firm Ascendis Pharma announced the European Commission approval for palopegteriparatide (Yorvipath), for treatment

Glenmark recall Esomeprazole Magnesium C

Glenmark Pharmaceuticals Inc., USA is recalling one lot of Esomeprazole Magnesium Delayed-Release Capsules. The recall

FDA Approves Evive Biotech’s Ryzneuta

FDA approves Evive Biotech’s Ryzneuta for the management of chemotherapy-induced neutropenia (incidence of infection, as

Bayer recall one lot of Vitrakvi (larotr

Bayer is recalling one lot of Vitrakvi® (larotrectinib) Oral Solution 20 mg/mL in 100mL glass

Cipla Pithampur unit gets FDA Warning le

Cipla in a statement informed that its Pithampur, Indore facility is issued an USFDA Warning

Merck’s Gefapixant (Lyfnua) for chroni

Merck in a statement announced that FDA’s advisory committee voted 12-1 that Gefapixant do not

Insanitary Conditions, Non-Aseptic Pract

USFDA Inspected Indian drug manufacturer Kilitch facility in Mumbai (FEI 3011853060) in Oct 2023. USFDA